Skip to main content
Top
Published in: Malaria Journal 1/2014

Open Access 01-12-2014 | Research

Perceptions and recommendations by scientists for a potential release of genetically modified mosquitoes in Nigeria

Authors: Patricia N Okorie, John M Marshall, Onoja M Akpa, Olusegun G Ademowo

Published in: Malaria Journal | Issue 1/2014

Login to get access

Abstract

Background

The use of genetically modified mosquitoes (GMMs) for the control of malaria and other mosquito-borne diseases has been proposed in malaria-endemic countries, such as Nigeria, which has the largest burden in Africa. Scientists are major stakeholders whose opinions and perceptions can adversely affect the success of the trials of GMMs if they are not involved early. Unfortunately, information on the awareness of Nigerians scientists and their overall perception of the GMMs is practically non-existent in the literature. Therefore, this study aimed at understanding how receptive Nigerian scientists are to a potential release of GMMs for the control of malaria.

Methods

The sample consisted of 164 scientists selected from academic and research institutions in Nigeria. Data were collected from participants using a semi-structured, self-administered questionnaire. Questions were asked about the cause and prevention of malaria, genetic modification and biotechnology. Specific questions on perception and acceptable conditions for the potential release of GM mosquitoes in Nigeria were also covered.

Results

All participants cited mosquitoes as one of several causes of malaria and used various methods for household control of mosquitoes. The main concerns expressed by the scientists were that GMMs can spread in an uncontrolled way beyond their release sites (89%) and will mate with other mosquito species to produce hybrids with unknown consequences (94.5%). Most participants (92.7%) agreed that it was important that before approving the release of GMMs in Nigeria, there had to be evidence of contingency measures available to remove the GMMs should a hazard become evident during the course of the release. In general, a majority (83.5%) of scientists who participated in this study were sceptical about a potential release in Nigeria, while 16.5% of the participants were in support.

Conclusions

Although a majority of the participants are sceptical about GMMs generally, most encourage the use of genetic modification techniques to make mosquitoes incapable of spreading diseases provided that there are contingency measures to remove GMMs if a hazard becomes evident during the course of the release.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO: World malaria report: 2010. 2010, Geneva, Switzerland: World Health Organization WHO: World malaria report: 2010. 2010, Geneva, Switzerland: World Health Organization
2.
go back to reference Okorie PN, McKenzie FE, Ademowo OG, Bockarie M, Kelly-Hope L: Nigeria anopheles vector database: an overview of 100 years’ research. PLoS One. 2011, 6: e28347-10.1371/journal.pone.0028347.PubMedCentralCrossRefPubMed Okorie PN, McKenzie FE, Ademowo OG, Bockarie M, Kelly-Hope L: Nigeria anopheles vector database: an overview of 100 years’ research. PLoS One. 2011, 6: e28347-10.1371/journal.pone.0028347.PubMedCentralCrossRefPubMed
3.
go back to reference Federal Ministry of Health: National malaria control programme 2012 1st & 2nd quarter report. 2012, Abuja, Nigeria: Nigeria National Malaria Control Programme Federal Ministry of Health: National malaria control programme 2012 1st & 2nd quarter report. 2012, Abuja, Nigeria: Nigeria National Malaria Control Programme
4.
go back to reference Ostera G, Gostin L: Biosafety concerns involving genetically modified mosquitoes to combat malaria and dengue in developing countries. JAMA. 2011, 305: 930-931. 10.1001/jama.2011.246.CrossRefPubMed Ostera G, Gostin L: Biosafety concerns involving genetically modified mosquitoes to combat malaria and dengue in developing countries. JAMA. 2011, 305: 930-931. 10.1001/jama.2011.246.CrossRefPubMed
5.
go back to reference Beech CJ, Koukidou M, Morrison NI, Alphey L: Genetically modified insects: science, use, status and regulation. Collect Biosaf Rev. 2012, 6: 66-124. Beech CJ, Koukidou M, Morrison NI, Alphey L: Genetically modified insects: science, use, status and regulation. Collect Biosaf Rev. 2012, 6: 66-124.
7.
go back to reference Beisel U, Boëte C: The flying public health tool: genetically modified mosquitoes and malaria control. Sci Cult (Lond). 2013, 22: 38-60. 10.1080/09505431.2013.776364.CrossRef Beisel U, Boëte C: The flying public health tool: genetically modified mosquitoes and malaria control. Sci Cult (Lond). 2013, 22: 38-60. 10.1080/09505431.2013.776364.CrossRef
8.
9.
go back to reference WHO: Progress and prospects for the use of genetically modified mosquitoes to inhibit disease transmission. 2009, Geneva, Switzerland: World Health Organization WHO: Progress and prospects for the use of genetically modified mosquitoes to inhibit disease transmission. 2009, Geneva, Switzerland: World Health Organization
10.
go back to reference Facchinelli L, Valerio L, Ramsey JM, Gould F, Walsh RK, Bond G, Robert MA, Lloyd AL, James AA, Alphey L, Scott TW: Field cage studies and progressive evaluation of genetically-engineered mosquitoes. PLoS Negl Trop Dis. 2013, 7: e2001-10.1371/journal.pntd.0002001.PubMedCentralCrossRefPubMed Facchinelli L, Valerio L, Ramsey JM, Gould F, Walsh RK, Bond G, Robert MA, Lloyd AL, James AA, Alphey L, Scott TW: Field cage studies and progressive evaluation of genetically-engineered mosquitoes. PLoS Negl Trop Dis. 2013, 7: e2001-10.1371/journal.pntd.0002001.PubMedCentralCrossRefPubMed
11.
go back to reference Reeves RG, Denton JA, Santucci F, Bryk J, Reed FA: Scientific standards and the regulation of genetically modified insects. PLoS Negl Trop Dis. 2012, 6: e1502-10.1371/journal.pntd.0001502.PubMedCentralCrossRefPubMed Reeves RG, Denton JA, Santucci F, Bryk J, Reed FA: Scientific standards and the regulation of genetically modified insects. PLoS Negl Trop Dis. 2012, 6: e1502-10.1371/journal.pntd.0001502.PubMedCentralCrossRefPubMed
12.
go back to reference Boëte C: Scientists and public involvement: a consultation on the relation between malaria, vector control and transgenic mosquitoes. Trans R Soc Trop Med Hyg. 2011, 105: 704-710. 10.1016/j.trstmh.2011.08.006.CrossRefPubMed Boëte C: Scientists and public involvement: a consultation on the relation between malaria, vector control and transgenic mosquitoes. Trans R Soc Trop Med Hyg. 2011, 105: 704-710. 10.1016/j.trstmh.2011.08.006.CrossRefPubMed
13.
go back to reference Macer D: Asia pacific perspectives on biotechnology and bioethics. 2008, Bangkok: UNESCO Macer D: Asia pacific perspectives on biotechnology and bioethics. 2008, Bangkok: UNESCO
14.
go back to reference Marshall J, Touré M, Traore M, Famenini S, Taylor C: Perspectives of people in Mali toward genetically-modified mosquitoes for malaria control. Malar J. 2010, 9: 128-10.1186/1475-2875-9-128.PubMedCentralCrossRefPubMed Marshall J, Touré M, Traore M, Famenini S, Taylor C: Perspectives of people in Mali toward genetically-modified mosquitoes for malaria control. Malar J. 2010, 9: 128-10.1186/1475-2875-9-128.PubMedCentralCrossRefPubMed
15.
go back to reference Marshall JM, Taylor CE: Malaria control with transgenic mosquitoes. PLoS Med. 2009, 6: e20-10.1371/journal.pmed.1000020.CrossRefPubMed Marshall JM, Taylor CE: Malaria control with transgenic mosquitoes. PLoS Med. 2009, 6: e20-10.1371/journal.pmed.1000020.CrossRefPubMed
16.
go back to reference Knols BGJ, Bossin HC, Mukabana WR, Robinson AS: Transgenic mosquitoes and the fight against malaria: managing technology push in a turbulent GMO world. Am J Trop Med Hyg. 2007, 77: 232-42.PubMed Knols BGJ, Bossin HC, Mukabana WR, Robinson AS: Transgenic mosquitoes and the fight against malaria: managing technology push in a turbulent GMO world. Am J Trop Med Hyg. 2007, 77: 232-42.PubMed
17.
go back to reference Marshall J: The Cartagena protocol and genetically modified mosquitoes. Nat Biotechnol. 2010, 28: 896-897. 10.1038/nbt0910-896.CrossRefPubMed Marshall J: The Cartagena protocol and genetically modified mosquitoes. Nat Biotechnol. 2010, 28: 896-897. 10.1038/nbt0910-896.CrossRefPubMed
18.
go back to reference Marshall JM, Touré MB, Traore MM, Taylor CE: Towards a quantitative assessment of public attitudes to transgenic mosquitoes: questions based on a qualitative survey in Mali. Asian Pacific J Mol Biol Biotechnol. 2010, 18: 251-273. Marshall JM, Touré MB, Traore MM, Taylor CE: Towards a quantitative assessment of public attitudes to transgenic mosquitoes: questions based on a qualitative survey in Mali. Asian Pacific J Mol Biol Biotechnol. 2010, 18: 251-273.
19.
go back to reference Touré YT, Knols BGJ: Genetically-modified mosquitoes for malaria control: requirements to be considered before field releases. Genetically modified mosquitoes for malaria control (ed C Boete). 2005, Georgetown: Eurekah/Landes Bioscience Touré YT, Knols BGJ: Genetically-modified mosquitoes for malaria control: requirements to be considered before field releases. Genetically modified mosquitoes for malaria control (ed C Boete). 2005, Georgetown: Eurekah/Landes Bioscience
20.
go back to reference Issa B, Baiyewu O: Quality of life of patients with diabetes mellitus in a Nigerian teaching hospital. Hong Kong J Psychiatry. 2006, 16: 27-33. Issa B, Baiyewu O: Quality of life of patients with diabetes mellitus in a Nigerian teaching hospital. Hong Kong J Psychiatry. 2006, 16: 27-33.
Metadata
Title
Perceptions and recommendations by scientists for a potential release of genetically modified mosquitoes in Nigeria
Authors
Patricia N Okorie
John M Marshall
Onoja M Akpa
Olusegun G Ademowo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2014
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-13-154

Other articles of this Issue 1/2014

Malaria Journal 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine